ASX Announcements Archive 2011
21 Dec 2011
Change of Director’s Interest Notice
19 Dec 2011
Finance News Network Interview with CEO Available on Circadian Website
13 Dec 2011
Change of Director’s Interest Notice
25 Nov 2011
Final Director’s Interest Notice
24 Nov 2011
Results of Annual General Meeting 24 November 2011
24 Nov 2011
Annual General Meeting Presentation 24 November 2011
24 Nov 2011
Chairman's Address to Annual General Meeting 24 November 2011
15 Nov 2011
Open Briefing with CEO & MD Robert Klupacs: CEO on IND status for VGX-100
31 Oct 2011
Circadian receives FDA IND approval to begin clinical trials with VGX-100 for the treatment of...
25 Oct 2011
Change of Director's Interest Notice
24 Oct 2011
Notice of Annual General Meeting and Explanatory Memorandum
20 Oct 2011
Change of Director's Interest Notice
18 Oct 2011
Final Director's Interest Notice
11 Oct 2011
Analyst Investment Research Reports Available on Circadian Website
10 Oct 2011
Healthscope commences clinical validation study of Circadian's Cancer Diagnostic
03 Oct 2011
Retirements from Circadian Board of Directors
30 Sep 2011
Circadian files IND with FDA for VGX-100 for the treatment of cancer patients with solid tumors
15 Sep 2011
Open Briefing with CEO & MD Robert Klupacs: FY12 Outlook and VGX-100 Progress
13 Sep 2011
VGX-100 identified as potential new therapy for Dry Eye Disease
12 Sep 2011
Circadian makes key appointment in clinical trials management
09 Sep 2011
Change of Director's Interest Notice
07 Sep 2011
Change of Director's Interest Notice
07 Sep 2011
Change of Director's Interest Notice
06 Sep 2011
Change of Director's Interest Notice
31 Aug 2011
Change in Substantial Holding for Optiscan Imaging Limited - Update
31 Aug 2011
Change of Director's Interest Notice
30 Aug 2011
Change of Director's Interest Notice
24 Aug 2011
Preliminary Final Report Appendix 4E Financial Year Ended 30 June 2011
25 Jul 2011
Change of Director's Interest Notice
18 Jul 2011
Change of Directors Interest Notice
14 Jul 2011
Open Briefing with CEO & MD Robert Klupacs
16 Jun 2011
Circadian provides market update on clinical development plans for VGX-100 in oncology and eye...
14 Jun 2011
Circadian launches Level 1 ADR program and OTCQX Quotation in US
10 Jun 2011
Substantial Holding Notice for Antisense Therapeutics Limited
07 Jun 2011
VEGF-C and VEGF-D identified as biomarkers for Avastin resistance in colorectal cancer patients
30 May 2011
Analyst Investment Research Reports Available on Circadian Website
18 Apr 2011
Circadian Technologies (Small Cap Showcase 2011) - Robert Klupacs Presentation
07 Apr 2011
Open Briefing with CEO & MD Robert Klupacs on First Phase I Clinical Trial of IMC - 3C5
06 Apr 2011
Circadian's VGX-100 Inhibits Tumour Growth in Models of Lung, Ovarian and Prostate Cancer
06 Apr 2011
Circadian's partner ImClone Systems commences first Phase 1 clinical trial of VEGFR-3 antibody...
22 Mar 2011
New issue announcement, application for quotation of additional securities and agreement
15 Feb 2011
31 December 2010 Half-Year Financial Report & Operational Achievements
14 Feb 2011
Finance News Network Interview with Circadian CEO Robert Klupacs
02 Feb 2011
Circadian Launches First Diagnostic for LAM Lung Disease with U.S. Partner
17 Jan 2011
VEGF-D Licence Agreement Open Briefing
13 Jan 2011
Chugai Pharmaceutical of Japan Grants Circadian Worldwide Licence to its VEGF-D Intellectual...
11 Jan 2011
2011 Biotech Showcase